|
IAC Express 2008 |
| Issue number 770: December 15, 2008 |
|
|
Please click here to subscribe to IAC Express
as well as other FREE IAC periodicals. |
|
|
Federal employees,
including military, may contribute to IAC by using code #10612 on their
Combined Federal Campaign pledge cards. |
|
|
Contents
of this Issue
Select a title to jump to the article. |
- New: CDC
issues provisional recommendations for use of pneumococcal vaccines
- FDA
approves expanded indication for use of Boostrix Tdap vaccine in people
ages 10-64 years
- New
interim VIS for PCV incorporates changes in recommendations for
vaccinating healthy children ages 2-4 years
- Audio of
NPR's interview with Dr. Paul Offit and Amanda Peet is available online
- Reminder:
December 18 is the date for CDC's webcast "The Immunization Encounter:
Critical Issues"
- IAC
updates its parent-education piece "MMR vaccine does not cause autism:
Examine the evidence!"
- IAC's
Video of the Week features a polio survivor's story
-
Important: Be sure to give influenza vaccine throughout the influenza
season--through spring 2009
- CDC
issues update on U.S. influenza activity during September 28-November 29
- VIS for
injectable influenza vaccine now in Turkish; VIS for yellow fever vaccine
now in Chinese, Tagalog, and Vietnamese
- Mark
your calendar: IZTA's teleconference on fundraising and outreach for
coalitions is planned for January 13, 2009
|
| |
| Abbreviations |
|
|
AAFP, American Academy of Family Physicians; AAP,
American Academy of Pediatrics; ACIP, Advisory Committee on Immunization
Practices; AMA, American Medical Association; CDC, Centers for Disease
Control and Prevention; FDA, Food and Drug Administration; IAC, Immunization
Action Coalition; MMWR, Morbidity and Mortality Weekly Report; NCIRD,
National Center for Immunization and Respiratory Diseases; NIVS, National
Influenza Vaccine Summit; VIS, Vaccine Information Statement; VPD,
vaccine-preventable disease; WHO, World Health Organization. |
| |
|
Issue 770: December 15, 2008 |
|
|
|
1. |
New: CDC issues provisional recommendations for use of pneumococcal vaccines
On December 8, CDC posted provisional
recommendations for use of
pneumococcal vaccines on the ACIP web section. Provisional
recommendations are those ACIP has voted on but that are not yet
approved by CDC or the Department of Health and Human Services
and have not yet been published in MMWR. The provisional
recommendations for pneumococcal vaccines are reprinted below.
ACIP PROVISIONAL RECOMMENDATIONS FOR USE OF PNEUMOCOCCAL
VACCINES
Date of ACIP vote: October 22, 2008
Date of posting of provisional recommendations: December 8, 2008
On October 22, 2008, the ACIP voted on new and revised
recommendations for the use of 23-valent pneumococcal
polysaccharide vaccine (PPSV23) for the prevention of invasive
pneumococcal disease. The new provisional recommendations are as
follows:
RECOMMENDATION FOR USE OF THE 23-VALENT PNEUMOCOCCAL
POLYSACCHARIDE VACCINE (PPSV23) AMONG ADULT CIGARETTE SMOKERS:
- Adults who smoke cigarettes are at substantially increased
risk for invasive pneumococcal disease.
- The ACIP recommends that cigarette smoking should be added to
the list of indications for PPSV23 in adults aged 19 through
64 years.
- Proposed wording of the revised recommendation: "Persons aged
19 through 64 years who smoke cigarettes should receive a
single dose of PPSV23 and smoking cessation counseling."
RECOMMENDATION FOR THE USE OF PPSV23 AMONG ADULTS WHO HAVE
ASTHMA:
- Asthma is an independent risk factor for invasive pneumococcal
disease.
- The ACIP recommends that asthma should be included among the
chronic pulmonary diseases (such as COPD and emphysema) that
are indications for PPSV23 in adults aged 19 through 64 years.
- Proposed wording of the revised recommendation: "Persons aged
19 through 64 years who have asthma should receive a single
dose of PPSV23."
REVISED RECOMMENDATION FOR USE OF PPSV23 AMONG AMERICAN INDIANS
AND ALASKA NATIVES
- American Indian/Alaska Native children aged 24 through 59
months:
- "Routine use of PPSV23 after PCV7 is not recommended for
Alaska Native or American Indian children aged 24 through 59
months. However, in special situations, public health
authorities may recommend the use of PPSV23 after PCV7 for
Alaska Native or American Indian Children aged 24 through 59
months who are living in areas in which risk of invasive
pneumococcal disease is increased."
- American Indian/Alaska Native adults:
- "Routine use of PPSV23 is not recommended for Alaska Native
or American Indian persons younger than 65 years old unless
they have underlying medical conditions that are PPSV23
indications. However, in special situations, public health
authorities may recommend PPSV23 for Alaska Natives and
American Indians aged 50 through 64 years who are living in
areas in which the risk of invasive pneumococcal disease is
increased."
REVISED RECOMMENDATION FOR REVACCINATION WITH PPSV23 IN HIGH
RISK CHILDREN AGED =<10 YEARS
- Immunocompromised persons or persons with sickle cell disease
or functional or anatomic asplenia are at highest risk for
serious pneumococcal infection and may have a rapid decline in
pneumococcal antibody levels after PPSV23.
- The ACIP recommends a single revaccination interval for these
persons in all age groups.
- Proposed wording for the revised recommendation: "A second
dose of PPSV23 is recommended 5 years after the first dose of
PPSV23 for persons aged >=2 years who are immunocompromised,
have sickle cell disease, or functional or anatomic asplenia."
Additional recommendations for use of PPSV23 and PCV7 can be
found in the following documents:
The 1997 ACIP recommendations for prevention of pneumococcal
disease. Available at: http://www.cdc.gov/mmwr/PDF/rr/rr4608.pdf
The [2000] ACIP recommendations for preventing pneumococcal
disease among infants and young children. Available at:
http://www.cdc.gov/mmwr/PDF/rr/rr4909.pdf
To access CDC's pneumococcal provisional recommendations, go to:
http://www.cdc.gov/vaccines/recs/provisional/downloads/pneumo-Oct-2008-508.pdf
All provisional ACIP recommendations can be found at
http://www.cdc.gov/vaccines/recs/provisional
All published ACIP recommendations can be accessed at
http://www.cdc.gov/vaccines/pubs/ACIP-list.htm
Back to top |
| |
|
|
2. |
FDA approves expanded indication for use of Boostrix Tdap vaccine in people
ages 10-64 years
On December 4, FDA approved GlaxoSmithKline's (GSK)
request to
supplement the biologics license application for the tetanus-diphtheria-acellular pertussis (Tdap) vaccine Boostrix. The
vaccine is now approved for use as a one-time booster for people
ages 10-64 years. Previously, it was approved for use in people
ages 10-18 years.
To access the December 4 approval letter, go to:
http://www.fda.gov/cber/approvltr/tdapboostrix120408L.htm
Note: The package insert posted on the FDA website is dated
December 2005. To view an updated package insert (dated December
2008) posted on the GSK website, go to:
http://us.gsk.com/products/assets/us_boostrix.pdf
Back to top |
| |
|
|
3. |
New interim VIS for PCV incorporates changes in recommendations for
vaccinating healthy children ages 2-4 years
On December 9, CDC issued an interim VIS for
pneumococcal
conjugate vaccine (PCV); it replaces the VIS for PCV dated
9/30/02. The new interim VIS incorporates changes made in the
recommendations for vaccinating healthy children ages 2-4 years
with the vaccine. Miscellaneous minor changes were also made.
CDC advises providers to use the new interim VIS immediately
when vaccinating children ages 2-4 years, but existing stocks
may continue to be used temporarily.
To access the 12/9/08 interim VIS for PCV, go to:
http://www.immunize.org/vis/pnPCV7.pdf
For information about the use of VISs, and for VISs in more than
35 languages, visit IAC's VIS web section at
http://www.immunize.org/vis
For general information about VISs from CDC's website go to:
http://www.cdc.gov/vaccines/pubs/vis
Back to top |
| |
|
|
4. |
Audio of NPR's interview with Dr. Paul Offit and Amanda Peet is available
online
Every Child by Two (ECBT) provided a brief
overview of a
National Public Radio (NPR) interview with Dr. Paul Offit and
Amanda Peet that aired on December 11 on NPR's morning news
program Morning Edition. Dr. Offit is the chief of Infectious
Diseases and the director of the Vaccine Education Center at the
Children's Hospital of Philadelphia, as well as the Maurice R.
Hilleman Professor of Vaccinology and professor of pediatrics at
the University of Pennsylvania School of Medicine. Film and
television actress Amanda Peet is ECBT's Vaccinate Your Baby
campaign spokesperson.
ECBT's overview is reprinted below.
Today on Morning Edition, science correspondent Jon Hamilton
reported on the vaccine-autism "debate" and set the record
straight. Mr. Hamilton interviewed both Vaccinate Your Baby
volunteer spokeswoman Amanda Peet and Dr. Paul Offit to counter
the recent onslaught of celebrity claims that immunizations and
the neurodevelopmental disorder are linked.
Both Ms. Peet and Dr. Offit pointed out the importance of
immunizing children, and the frightening consequences of
exempting--especially for the 500,000 vulnerable Americans who
cannot be vaccinated due to autoimmune disorders.
You can listen to the 5-minute segment on NPR's web site by
clicking
here.
Back to top |
| |
|
|
5. |
Reminder: December 18 is the date for CDC's webcast "The Immunization
Encounter: Critical Issues"
CDC will present a webcast, "The Immunization
Encounter:
Critical Issues," on December 18 from 12 noon-2PM EST. The
program will address issues related to the routine encounter at
an immunization clinic. Topics include patient and parent
communication and education, vaccine storage and handling,
preparing for medical emergencies, screening for
contraindications and precautions to vaccination, vaccine
administration, records and documentation, the Vaccine Adverse
Event Reporting System, and the Vaccine Injury Compensation
Program. Continuing education credits will be offered.
Additional information about the program is available at
http://www2a.cdc.gov/phtn/imm-encounter2008 No registration is
necessary to access the webcast via an Internet connection. The
link to the webcast is available at
http://www2a.cdc.gov/phtn/webcast/imm-encounter2008 The webcast
will be accessible through an Internet connection until January
20, 2009, and will become available as a self-study DVD and
Internet-based program in January 2009.
Back to top |
| |
|
|
6. |
IAC updates its parent-education piece "MMR vaccine does not cause autism:
Examine the evidence!"
IAC recently updated "MMR vaccine does not cause
autism: Examine
the evidence!" Two additional references have been added to the
list of articles demonstrating there is no connection between
MMR vaccine and autism.
To access the updated piece, go to:
http://www.immunize.org/catg.d/p4026.pdf
IAC's Print Materials web section offers healthcare
professionals and the public approximately 250 FREE English-language materials (many also available in translation), which
we encourage website users to print out, copy, and distribute
widely. To access all of IAC's free print materials, go to:
http://www.immunize.org/printmaterials
Back to top |
| |
|
|
7. |
IAC's Video of the Week features a polio survivor's story
IAC encourages IAC Express readers to watch a
two-minute video
about the experiences recounted in the book "Twin Voices: A
memoir of polio, the forgotten killer." Written by Janice Flood
Nichols, the book chronicles a 1953 polio outbreak that claimed
the life of Ms. Nichols' twin brother and left her with
paralytic polio. Ms. Nichols is currently the interim executive
director of Voices for Vaccines, an immunization advocacy
organization.
Titled "A Memoir of Polio," the video will be available on the
home page of IAC's website through December 21. To access it, go
to: http://www.immunize.org and click on the image under the
words Video of the Week, which you'll find toward the top of the
page.
Remember to bookmark the URL above to view a new video every
Monday. While you're at our homepage, we encourage you to browse
around--you're sure to find resources and information that will
enhance your practice of immunization delivery.
Back to top |
| |
|
|
8. |
Important: Be sure to give influenza vaccine throughout the influenza
season--through spring 2009
Influenza vaccine for the 2008-09 influenza
season is widely
available, and the supply is robust. If you run out of vaccine
in your work setting, please place another order. Influenza
vaccination efforts should continue through the holiday season
and into the spring months of 2009.
For abundant information about influenza vaccination, visit the
following two websites often. They are continually updated with
the latest resources:
The National Influenza Vaccine Summit website at
http://www.preventinfluenza.org
CDC's Seasonal Flu web section at http://www.cdc.gov/flu
Back to top |
| |
|
|
9. |
CDC
issues update on U.S. influenza activity during September 28-November 29
CDC published "Update: Influenza Activity--United
States,
September 28-November 29, 2008" in the December 12 issue of
MMWR. Portions of the article are reprinted below.
During September 28-November 29, 2008, influenza activity
remained low in the United States. Of the few influenza viruses
characterized thus far this season, most are antigenically
related to the strains included in the 2008-09 influenza
vaccine. Oseltamivir-resistant influenza A (H1N1) viruses have
been detected, but currently available data are insufficient to
predict their prevalence for the 2008-09 season. This report
summarizes U.S. influenza activity since the last update and
reviews new influenza vaccine recommendations for the current
season. . . .
Antigenic Characterization
WHO collaborating laboratories in the United States are
requested to submit a subset of their influenza-positive
respiratory specimens to CDC for further antigenic
characterization. CDC has antigenically characterized 30
influenza viruses collected by U.S. laboratories during the
2008-09 season, including 20 influenza A (H1N1), three influenza
A (H3N2), and seven influenza B viruses. Twenty-seven of the 30
viruses were antigenically related to the components included in
the 2008-09 influenza vaccine (A/Brisbane/59/2007-like (H1N1),
A/Brisbane/10/2007-like (H3N2), and B/Florida/04/2006-like). The
other three influenza B viruses belong to the B/Victoria/02/87
lineage. . . .
Pneumonia- and Influenza-Related Mortality
For the week ending November 29, 2008, pneumonia and influenza
(P&I) was reported as an underlying or contributing cause of
death for 6.7% of all deaths reported to the 122 Cities
Mortality Reporting System. This is below the epidemic threshold
of 7.1% for that period. Since September 28, 2008, the weekly
percentage of deaths attributed to P&I ranged from 6.0%-6.7%,
remaining below the epidemic threshold. . . .
Influenza-Related Pediatric Mortality
No influenza-related pediatric deaths have been reported for the
2008-09 season. . . .
On average, influenza is estimated to cause approximately
226,000 hospitalizations and 36,000 deaths per year in the
United States. Annual vaccination remains the best method for
preventing influenza and its potentially severe complications.
The Advisory Committee on Immunization Practices (ACIP) recently
expanded its recommendations for influenza vaccination to
include all children aged 6 months-18 years. In addition,
influenza vaccine should be administered to other persons at
high risk for influenza-related complications, close contacts of
those at high risk (including healthcare workers), and anyone
else who wants to decrease their risk for influenza. . . .
Vaccination remains the cornerstone of influenza prevention
efforts. Influenza vaccination can prevent influenza infections
from strains that are sensitive or resistant to antiviral
medications; the influenza A (H1N1) viruses found to be
oseltamivir resistant are antigenically similar to the
components included in the 2008-09 vaccine. . . .
CDC continues to conduct surveillance to provide up-to-date
recommendations regarding prevention and treatment of influenza.
Influenza surveillance reports for the United States are posted
online weekly during October-May and are available at
http://www.cdc.gov/flu/weekly/fluactivity.htm Additional
information regarding influenza viruses, influenza surveillance,
influenza vaccine, and avian influenza is available at
http://www.cdc.gov/flu
To access a web-text (HTML) version of the complete article, go
to: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5749a3.htm
To access a ready-to-print (PDF) version of this issue of MMWR,
go to: http://www.cdc.gov/mmwr/PDF/wk/mm5749.pdf
To receive a FREE electronic subscription to MMWR (which
includes new ACIP recommendations), go to:
http://www.cdc.gov/mmwr/mmwrsubscribe.html
Back to top |
| |
|
|
10. |
VIS for injectable influenza vaccine now in Turkish; VIS for yellow fever
vaccine now in Chinese, Tagalog, and Vietnamese
Dated 7/24/08, the current VIS for trivalent
inactivated
influenza vaccine (TIV; injectable) is now available in Turkish.
Dated 11/9/04, the current VIS for yellow fever vaccine is now
available in Chinese, Tagalog, and Vietnamese. IAC gratefully
acknowledges Mustafa Kozanoglu, MD, and Murat Serbest, MD, for
the influenza VIS translation, and the California Department of
Public Health, Immunization Branch for the yellow fever vaccine
translations.
VIS FOR TIV
To access the Turkish version of the VIS for TIV, go to:
http://www.immunize.org/vis/tu_flu06.pdf
To access the English version of the VIS for TIV, go to:
http://www.immunize.org/vis/2flu.pdf
NOTE: The VIS for TIV comes in additional languages, including
Spanish. To access them, go to:
http://www.immunize.org/vis/vis_flu_inactive.asp Click on the
link to the pertinent language.
VIS FOR YELLOW FEVER VACCINE
To access the Chinese version of the VIS for yellow fever
vaccine, go to: http://www.immunize.org/vis/ch_yf.pdf
To access the Tagalog version of the VIS for yellow fever
vaccine, go to: http://www.immunize.org/vis/ta_yf.pdf
To access the Vietnamese version of the VIS for yellow fever
vaccine, go to: http://www.immunize.org/vis/vn_yf.pdf
To access the English version of the VIS for yellow fever
vaccine, go to: http://www.immunize.org/vis/yfever04.pdf
NOTE: The VIS for yellow fever vaccine also comes in Spanish. To
access it, go to: http://www.immunize.org/vis/sp_yf04.pdf
For information about the use of VISs, and for VISs in more than
35 languages, visit IAC's VIS web section at
http://www.immunize.org/vis
For general information about VISs from CDC's website go to:
http://www.cdc.gov/vaccines/pubs/vis
Back to top |
| |
|
|
11. |
Mark your calendar: IZTA's teleconference on fundraising and outreach for
coalitions is planned for January 13, 2009
The Immunization Coalitions Technical Assistance
Network (IZTA)
conference call on January 13, 2009, will discuss ideas for
coalitions that are looking to make the most of their limited
resources for fundraising, promotion, and partnership
development. IZTA is a program of the Center for Health
Communication, Academy for Educational Development (AED).
The presenter is AED's Erik Wang. His professional career
includes developing creative public/private partnerships and
cause-related marketing campaigns for Best Buy, Magic Johnson
Foundation, National Basketball Association, and General Mills.
For this call, IZTA is encouraging coalitions that have a
specific fundraising or partnership challenge to email a
description of their situation to IZTA. The call will include
brainstorming ideas about a few of the submitted situations.
Send your email to izta@aed.org
To register for the conference call, send an email to
izta@aed.org Include this message in the subject line: "Sign me
up for the fundraising and outreach call."
To access earlier programs, go to:
http://www.izta.org/confcall.cfm
Back to top |
| |
|
|
